SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    R. Buzzoni, S. Pusceddu, E. Bajetta, F. De Braud, M. Platania, C. Iannacone, M. Cantore, A. Mambrini, A. Bertolini, O. Alabiso, A. Ciarlo, C. Turco, V. Mazzaferro, Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study, Annals of Oncology, 2014,

    CrossRef

  2. 2
    Atsushi Umemura, Eek Joong Park, Koji Taniguchi, Jun Hee Lee, Shabnam Shalapour, Mark A. Valasek, Mariam Aghajan, Hayato Nakagawa, Ekihiro Seki, Michael N. Hall, Michael Karin, Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition, Cell Metabolism, 2014, 20, 1, 133

    CrossRef

  3. 3
    Kan Chen, Kwan Man, Herold J. Metselaar, Harry L. A. Janssen, Maikel P. Peppelenbosch, Qiuwei Pan, Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation, Liver Transplantation, 2014, 20, 3
  4. 4
    Robert T. Abraham, Too Little mTORC1 Activity Injures the Liver, Cell Metabolism, 2014, 20, 1, 4

    CrossRef

  5. 5
    Akio Nakashima, Keiko Tanimura-Ito, Noriko Oshiro, Satoshi Eguchi, Takafumi Miyamoto, Ayaka Momonami, Shinji Kamada, Kazuyoshi Yonezawa, Ushio Kikkawa, A positive role of mammalian Tip41-like protein, TIPRL, in the amino-acid dependent mTORC1-signaling pathway through interaction with PP2A, FEBS Letters, 2013, 587, 18, 2924

    CrossRef

  6. 6
    Siddharth Singh, Preet Paul Singh, Hepatocellular cancer risk in diabetes: Not all diabetics are the same, Hepatology, 2013, 58, 6